Limitations of Current Cancer Theranostics

Mhaske, Akshada; Dighe, Sayali; Ghosalkar, Shruti; Tanna, Vidhi; Ravikumar, Padmini; Sawarkar, Sudhir

doi:10.1007/978-3-030-76263-6_12

Cited by 3 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumor microenvironment's complexity significantly influences the delivery and efficacy of nanotheranostics, necessitating more research into its role in drug resistance. Lastly, despite the targeted approach of nanotheranostics, systemic side effects can still occur, underscoring the need for understanding and mitigating these effects for the safe application of nanotheranostics in cancer treatment 188 . Theranostic nanoparticles can help to overcome cancer therapeutic challenges such as drug resistance, low tissue specificity, and harm to normal tissues.…”

Section: Breakthroughs Of Nanoparticles For Targeted Delivery To Soli...mentioning

confidence: 99%

“…The intricate design and large-scale manufacturing of nanotheranostics that can evade the body's defenses and accurately target tumor Lastly, despite the targeted approach of nanotheranostics, systemic side effects can still occur, underscoring the need for understanding and mitigating these effects for the safe application of nanotheranostics in cancer treatment. 188 Theranostic nanoparticles can help to overcome cancer therapeutic challenges such as drug resistance, low tissue specificity, and harm to normal tissues. They can also reduce toxicity, improve solubility, and enhance accumulation within the target tissue.…”

Section: Polymeric Nanotheranosticsmentioning

confidence: 99%

See 1 more Smart Citation

Polymeric nanotheranostics for solid tumor management: Recent developments and global regulatory landscape

Sardar,

Kashinath,

Gupta

et al. 2024

Polymers for Advanced Techs

View full text Add to dashboard Cite

Polymeric nanotheranostics have emerged as promising vehicles for diagnosis‐cum‐targeted therapy in solid tumors, offering precise delivery of therapeutic agents at the site of solid tumors and minimizing systemic side effects. This article summarizes the latest developments in using polymeric nanoparticles for specific treatment strategies in solid tumors. It explores the various methods these nanoparticles utilize for targeted medication delivery. This includes passive targeting through the amplified permeability and retention effect, active targeting via interactions between ligands and receptors, and stimuli‐responsive release mechanisms such as pH, temperature, and enzymatic triggers. Furthermore, we highlight recent developments in stimuli‐responsive polymeric nanoparticles, which enable controlled drug release in response to specific cues in the tumor microenvironment, thus enhancing therapeutic efficacy. Also, we focus on the theranostic polymeric nanoparticles, which are used for diagnosing and treating solid tumors. We discuss critical regulatory considerations and the regulatory bodies of different countries that regulate nanomedicines' safety, efficacy, quality, and manufacturing processes. Overall, this review provides insights into the latest innovations in polymeric nanoparticles for targeted therapy in solid tumors, elucidating their mechanisms of action, stimuli‐responsive properties, and regulatory pathways, which collectively contribute to developing effective and safe nanomedicines for cancer treatment.

show abstract

Section: Breakthroughs Of Nanoparticles For Targeted Delivery To Soli...mentioning

confidence: 99%

Section: Polymeric Nanotheranosticsmentioning

confidence: 99%

Polymeric nanotheranostics for solid tumor management: Recent developments and global regulatory landscape

Sardar,

Kashinath,

Gupta

et al. 2024

Polymers for Advanced Techs

View full text Add to dashboard Cite

show abstract

“…Further research is required in design and manufacturing, action and response for interaction between biomolecules and nanotheranostics, regulatory and safety aspects, and translation to clinical applications. To specify, the design and manufacturing of nanotheranostics is a complex process that requires careful consideration of various factors such as size, shape, surface chemistry, and biocompatibility (Mhaske et al, 2021). There are still challenges in developing nanotheranostics with optimal properties for specific applications.…”

Section: Research Gapmentioning

confidence: 99%

Revolutionising Cancer Diagnosis and Treatment: A Review on Advancements in Nanomaterial-based Theranostics

Jabarkhil,

Azizi,

Imam

et al. 2023

IJEMM

View full text Add to dashboard Cite

The persistent struggle against cancer has given rise to the development of nanotheranostics, a domain that integrates therapeutic and diagnostic capabilities within nanoscale structures. This paper explores advancements in nanomaterials and nanoparticles for cancer nanotheranostics, focusing on their design, significance, and applications. The incorporation of biocompatible nanoparticles in cancer therapy offers personalised, targeted approaches while minimising side effects. The use of nanomaterials such as metals, polymers, and lipids enable precise drug delivery and imaging. Various imaging modalities, including ultrasound and fluorescence, complement therapeutic strategies for enhanced precision. Critical parameters for nanomaterial selection and design are discussed, emphasising biocompatibility, targeting efficiency, and drug delivery capacity. Biocompatibility ensures safe interactions within biological systems, requiring mitigation of toxicological concerns through strategies like anti-inflammatory peptides or ligand-functionalization. Targeting efficiency combines passive and active targeting to enhance specificity, reshaping cancer diagnostics and therapy. Drug delivery capacity is achieved through engineered core-shell structures with distinct properties, including liposomes, micelles, and dendrimers, each tailored for targeted therapy and imaging. This paper also discusses the advancements in the field of cancer treatment using nanotheranostics and its economic impact on the Canadian healthcare systems while following the ethical guidelines towards patients’ consent, privacy, and the proper use of emerging technologies.

show abstract

“…Despite significant advancements in medical science, the complexity and heterogeneity of cancer pose major obstacles in achieving optimal treatment outcomes. The one-size-fits-all approach, where patients with the same tumor type and genetic profile receive identical treatment protocols, fails to account for the varied responses and individual differences in drug efficacy [2].…”

Section: Introductionmentioning

confidence: 99%

PTOLEMI: Personalized Cancer Treatment through Machine Learning-Enabled Image Analysis of Microfluidic Assays

Moerdler,

Krasner,

Orenbuch

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Contemporary personalized cancer diagnostic approaches encounter multiple challenges. The presence of cellular and molecular heterogeneity in patient samples introduces complexities to analysis protocols. Conventional analyses are manual, reliant on expert personnel, time-intensive, and financially burdensome. The copious data amassed for subsequent analysis strains the system, obstructing real-time diagnostics at the “point of care” and impeding prompt intervention. This study introduces PTOLEMI: Python-based Tensor Oncological Locator Examining Microfluidic Instruments. PTOLEMI stands out as a specialized system designed for high-throughput image analysis, particularly in the realm of microfluidic assays. Utilizing a blend of machine learning algorithms, PTOLEMI can process large datasets rapidly and with high accuracy, making it feasible for point-of-care diagnostics. Furthermore, its advanced analytics capabilities facilitate a more granular understanding of cellular dynamics, thereby allowing for more targeted and effective treatment options. Leveraging cutting-edge AI algorithms, PTOLEMI rapidly and accurately discriminates between cell viability and distinct cell types within biopsy samples. The diagnostic process becomes automated, swift, precise, and resource-efficient, rendering it well-suited for point-of-care requisites. By employing PTOLEMI alongside a microfluidic cell culture chip, physicians can attain personalized diagnostic and therapeutic insights. This paper elucidates the evolution of PTOLEMI and showcases its prowess in analyzing cancer patient samples within a microfluidic apparatus. While the integration of machine learning tools into biomedical domains is undoubtedly in progress, this study’s innovation lies in the fusion of PTOLEMI with a microfluidic platform—an integrated, rapid, and independent framework for personalized drug screening-based clinical decision-making.

show abstract

Limitations of Current Cancer Theranostics

Cited by 3 publications

References 81 publications

Polymeric nanotheranostics for solid tumor management: Recent developments and global regulatory landscape

Polymeric nanotheranostics for solid tumor management: Recent developments and global regulatory landscape

Revolutionising Cancer Diagnosis and Treatment: A Review on Advancements in Nanomaterial-based Theranostics

PTOLEMI: Personalized Cancer Treatment through Machine Learning-Enabled Image Analysis of Microfluidic Assays

Contact Info

Product

Resources

About